Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study to Evaluate [18F]ACI-19626 As a Potential PET Radioligand for Imaging TDP-43 Inclusions in the Brain of Patients with Suspected TDP-43 Proteinopathies Compared with Healthy Controls

Next Previous
Search
Trial Profile

Phase 1 Study to Evaluate [18F]ACI-19626 As a Potential PET Radioligand for Imaging TDP-43 Inclusions in the Brain of Patients with Suspected TDP-43 Proteinopathies Compared with Healthy Controls

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 01 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACI 19626 (Primary)
  • Indications Frontotemporal dementia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AC Immune

    • Most Recent Events

    • 01 Apr 2025 New trial record
    • 13 Mar 2025 According to AC Immune media release, this study is Phase 1 clinical trial of TDP-43-PET tracer ACI-19626 in genetic frontotemporal dementia (FTD) is ongoing with initial clinical data expected in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top